Skip to main content

Congress of Clinical Dermatology (CCD), 2025

Filter
Close
Content type:
Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II
Alexa B. Kimball, Amit Garg, Lev-Tov Hadar, et al.
Poster
Bimekizumab efficacy and safety through 5 years in patients with moderate to severe plaque psoriasis in the US and Canada
Blauvelt Andrew, Khattri Saakshi, Rich Phoebe, et al.
Poster